てんかん市場：タイプ別、治療法別、用途別、エンドユーザー別、地域別、2026-2032年

てんかん市場の評価、2026-2032年

世界保健機関（WHO）の推計によると、てんかんの有病率は増加傾向にあり、全世界で約5,000万人がその影響を受けています。さらに、メンタルヘルスケアの強化や、てんかんにまつわる偏見をなくすことを目的とした政府の支援策が、治療へのアクセスや技術革新を促進する雰囲気を作り出しています。2024年には28億2,000万米ドルを超え、2032年には47億7,000万米ドルに達します。

さらに、新しい診断ツールの導入や治療の選択肢といった技術的改善により、患者の転帰が改善し、早期介入が促進されるため、2026年から2032年までのCAGRは約7.52%で成長すると予想されます。

てんかん疾患の有病率の増加は、てんかん市場を牽引するか？

てんかんの有病率が全年齢層で上昇するにつれ、世界のてんかん市場は急速に拡大しています。世界保健機関（WHO）の2024年3月の報告書によると、世界で6,500万人以上がてんかんを患っており、2022年から2023年の間に新たに記録された症例は24%増加するという厄介な数字が出ています。2024年2月、国際抗てんかん連盟（ILAE）は、先進諸国における発症率は10万人年当たり61.4人に上り、小児患者は32%増加していると発表しました。2024年1月の業界予測によると、てんかん治療薬の世界市場規模は2023年に183億米ドル、2028年までのCAGRは9.8%と予想されています。

2024年2月、薬剤耐性てんかんに対するファイザーの遺伝子治療薬がFDAから早期承認され、2024年3月にはグラクソ・スミスクラインの高度な神経調節装置が承認されました。2024年1月、米国政府は国立衛生研究所を通じててんかんの研究開発と治療開発に28億米ドルを拠出し、欧州委員会は2024年4月、加盟国全体でてんかん治療へのアクセスを向上させるため、5億ユーロのプロジェクトを開始しました。

抗てんかん薬の高価格はてんかん市場の成長を抑制するか？

抗てんかん薬（AED）の高価格は、特に中低所得国において、てんかん市場の拡大を妨げると予想されます。多くの患者は、これらの重要な薬剤を受け取るために経済的な困難に直面しており、それがコンプライアンス違反や効果的でない治療につながる可能性があります。2024年1月に発表されたEpilepsy Foundationの調査によると、米国ではてんかん患者の半数近くが治療薬の購入に困っており、最適な治療結果を得るための重要なハードルとなっています。このような経済的負担は、患者の健康に影響を及ぼすだけでなく、救急外来受診や入院など、未治療のてんかんに関連するヘルスケア費用の増加にもつながります。

さらに、新規のAEDや先進的な治療にかかる費用は、一般的に法外に高額であり、保険償還されない可能性があるため、状況をさらに悪化させる可能性があります。2024年3月、Health Affairs誌に掲載された報告書によると、AEDの年間平均費用は過去5年間で30％上昇しており、治療へのアクセスと公平性についての懸念が高まっています。その結果、患者や医療制度への継続的な経済的負担が市場拡大の妨げとなり、新規かつ効果的なてんかん治療法の開発と導入が阻害される可能性があります。このようなコストの障壁に対処することは、治療へのアクセスを向上させ、てんかん分野の成長を促進する上で極めて重要です。

目次

第1章 世界のてんかん市場のイントロダクション

• 市場の導入
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次資料
• データソース一覧

第4章 世界のてんかん市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 世界のてんかん市場、タイプ別

• 概要
• 特発性
• 症候性
• 潜因性

第6章 世界のてんかん市場：治療法別

• 概要
• 抗てんかん薬
• 外科手術
• 迷走神経刺激療法
• ケトン食

第7章 世界のてんかん市場：用途別

• 概要
• 全般発作
• 焦点発作
• 欠神発作
• 強直間代発作

第8章 世界のてんかん市場：エンドユーザー別

• 概要
• 病院
• 診療所
• 外来手術センター
• 在宅医療

第9章 世界のてんかん市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東およびアフリカ

第10章 世界のてんかん市場の競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第11章 企業プロファイル

• UCB S.A.
• Abbott Laboratories
• GlaxoSmithKline plc
• Bausch Health Companies Inc.
• Sumitomo Pharma Co. Ltd
• H. Lundbeck A/S
• Sanofi
• Viatris Inc.
• Novartis AG
• Johnson & Johnson

第12章 付録

• 関連調査

Epilepsy Market Valuation - 2026-2032

The increasing prevalence of epilepsy, estimated by the World Health Organization to impact around 50 million people globally, fuels demand for improved therapies and management measures. Furthermore, supportive government measures targeted at enhancing mental health care and lowering the stigma associated with epilepsy are creating a more conducive atmosphere for treatment access and innovation. These variables, when combined, are driving significant growth in the epilepsy market.is surpassing USD 2.82 Billion in 2024 and reaching USD 4.77 Billion by 2032.

Furthermore, technological improvements, such as the introduction of novel diagnostic tools and treatment choices, improve patient outcomes and encourage early intervention is expected to grow at a CAGR of about 7.52% from 2026 to 2032.

Will Rising Prevalence of Epilepsy Disease Drive the Epilepsy Market?

The worldwide epilepsy market is rapidly expanding as the prevalence of epilepsy rises across all age groups. According to the World Health Organization's March 2024 report, over 65 million individuals worldwide suffer from epilepsy, with a troubling 24% increase in new cases documented between 2022 and 2023. In February 2024, International League against Epilepsy (ILAE) show that the incidence rate has climbed to 61.4 cases per 100,000 person-years in developed countries, with a 32% increase in pediatric cases. According to a January 2024 industry estimate, the global epilepsy therapeutics market would be worth USD 18.3 Billion in 2023, with a CAGR of 9.8% expected through 2028, owing mostly to improved diagnosis rates and novel treatment options.

In February 2024, Pfizer's gene therapy treatment for drug-resistant epilepsy was granted fast-track designation by the FDA, while GlaxoSmithKline's sophisticated neuromodulation device received regulatory approval in March 2024. In January 2024, the US government dedicated USD 2.8 Billion for epilepsy research and treatment development through the National Institutes of Health, while the European Commission started a €500 million project in April 2024 to increase epilepsy care access across member states.

Will High Cost of Antiepileptic Drugs Hinder the Growth of the Epilepsy Market?

The high cost of antiepileptic medications (AEDs) is expected to stymie the expansion of the epilepsy market, particularly in low- and middle-income nations. Many patients confront financial difficulties to receiving these critical medications, which can lead to noncompliance and ineffective therapy. According to an Epilepsy Foundation research published in January 2024, nearly half of people with epilepsy in the United States have difficulty purchasing their drugs, underlining a key hurdle in attaining optimal treatment outcomes. This financial burden not only has an influence on patient health, but it also leads to higher healthcare expenses associated with untreated epilepsy, such as emergency room visits and hospitalizations.

Furthermore, the cost of novel AEDs and advanced therapies might compound the situation, as these treatments are typically prohibitively expensive and may not be reimbursed by insurance. In March 2024, according to a report published in Health Affairs, the average annual cost of AEDs has risen by 30% in the last five years, raising concerns about treatment access and equity. As a result, the continuous financial burden on patients and healthcare systems may hinder market expansion, impeding the development and implementation of novel and effective epilepsy treatments. Addressing these cost barriers will be critical to enhancing access to care and driving growth in the epilepsy sector.

Category-Wise Acumens

Will Rising Demand for Idiopathic Drive the Epilepsy Market?

The increasing demand for idiopathic epilepsy treatments is expected to have a substantial impact on the epilepsy industry and its dominance. Pharmaceutical companies are increasing their R&D efforts as more patients seek effective treatments for this common type of epilepsy. For instance, in October 2023, UCB announced positive clinical trial findings for a novel medicine targeting idiopathic generalized epilepsy, demonstrating the industry's commitment to meeting this unmet need.

In September 2023, the U.S. FDA approved a new treatment specifically for idiopathic epilepsy, underscoring regulatory encouragement for innovation in this field. Moreover, in July 2023, the European Medicines Agency unveiled a strategic plan to boost research in neurological disorders, including epilepsy, indicating a growing focus on improving patient outcomes through better access to care and funding for research initiatives.

However, the symptomatic group is growing the quickest, owing to advances in diagnostic procedures and more knowledge of underlying illnesses that can cause seizures. The increased identification of symptomatic epilepsy, which is associated with structural or metabolic disorders, is encouraging more patients to seek treatment, expanding this segment's market position.

Will High Incidence of Generalized Seizures Fuel the Epilepsy Market?

The increasing prevalence of generalized seizures is likely to fuel expansion in the epilepsy market, emphasizing the need for improved treatments. Pharmaceutical companies are focusing more on creating tailored medicines as a large percentage of people suffer from generalized seizures. In October 2023 Eisai stated that a clinical trial for a novel medicine specifically intended for generalized tonic-clonic seizures had been successful, showing the industry's response to the growing demand for effective therapies.

In September 2023, the FDA authorized a novel version of an existing medicine for treating generalized seizures, demonstrating regulatory support for epilepsy care innovation. Furthermore, in July 2023, the World Health Organization highlighted the importance of addressing seizure disorders in its health initiatives, emphasizing the need for improved global access to epilepsy treatments, thereby increasing the focus on generalized seizure management in public health strategies.

Meanwhile, the focal seizures segment is expanding the fastest, driven by increased awareness and diagnosis of this type of epilepsy. With developments in treatment modalities and personalized approaches to care, more individuals with focal seizures are being diagnosed and managed, boosting growth in this market as healthcare practitioners focus more on tailored therapy for specific seizure types.

Country/Region-wise

Will Rising Investments in Research and Developments in North America Drive the Epilepsy Market?

Rising investment in research and development (R&D) in North America is expected to considerably impact the epilepsy market. According to a report from the National Institutes of Health (NIH), funding for neurological research, including epilepsy, will exceed USD 2 Billion by 2023, demonstrating the government's commitment to improving treatment choices. Companies such as UCB and Jazz Pharmaceuticals have also announced significant increases in their R&D budgets, with UCB intending to invest USD 1.5 Billion in innovative therapeutics over the next five years, with the goal of developing new antiepileptic drugs that address unmet patient requirements.

Furthermore, technological improvements and collaboration between pharmaceutical corporations and academic institutions have accelerated the rate of invention. In March 2024, the FDA authorized a new seizure monitoring gadget manufactured by Medtronic, demonstrating the expanding convergence of technology and epilepsy therapy. These investments not only help to create novel medicines, but also improve diagnostic tools and patient management procedures, all of which contribute to the dominance and efficacy of the North American epilepsy market.

Will Growing Awareness of Epilepsy Disorder in Asia Pacific Propel the Epilepsy Market?

The increasing awareness of epilepsy problems in Asia Pacific is predicted to greatly boost the epilepsy industry. Recent attempts by health organizations and governments to educate the public about epilepsy have resulted in a greater awareness of the condition and its implications. For instance, in February 2024, World Health Organization (WHO) report published found that approximately 75% of people with epilepsy in low- and middle-income nations go untreated, underscoring the critical need for awareness and care. This increased awareness encourages more people to seek diagnosis and treatment, which drives demand for antiepileptic medications and therapies.

Furthermore, regional governments are actively promoting programs to improve epilepsy treatment. In January 2024, the Indian government announced a national effort to improve mental health services, including specialized epilepsy care, with the goal of closing the country's treatment gap. Companies such as Sun Pharmaceutical have responded by focusing more on creating affordable epilepsy treatments for the Asian market. As awareness grows, both governmental and private funding are likely to flow into research, education, and the development of more effective therapies, boosting the region's growth in the epilepsy industry even further.

Competitive Landscape

The competitive landscape of the epilepsy market is characterized by a diverse array of companies ranging from large pharmaceutical firms to specialized biotech startups. This sector is marked by continuous innovation, with a focus on developing new antiepileptic drugs (AEDs), including novel mechanisms of action and formulations aimed at improving patient adherence and minimizing side effects. Additionally, the rise of digital therapeutics and wearable technology for seizure monitoring is reshaping the market dynamics, fostering partnerships between tech companies and healthcare providers. Regulatory approvals and clinical trial outcomes play critical roles in shaping competition, as companies strive to differentiate their products in a crowded marketplace while addressing unmet needs in epilepsy treatment.

Some of the prominent players operating in the epilepsy market include:

UCB S.A.

Abbott Laboratories

GlaxoSmithKline plc

Bausch Health Companies, Inc.

Sumitomo Pharma Co. Ltd

Lundbeck A/S

Sanofi

Viatris, Inc.

Novartis AG

Latest Developments

In July 2023, Neurelis introduced a new device for dispensing its nasal spray treatment for acute seizures, enhancing patient accessibility in emergency scenarios. This idea aims to improve immediate care for seizure occurrences.

In July 2023, The FDA approved a new medication for focal seizures, expanding the available medicines in the epilepsy market. This approval demonstrates regulatory support for innovation as well as the need of appropriate management options for varied seizure types.

Epilepsy Market, By Category

• Type:
• Idiopathic
• Symptomatic
• Cryptogenic
• Treatment:
• Antiepileptic Drugs
• Surgery
• Vagus Nerve Stimulation
• Ketogenic Diet
• Application:
• Generalized Seizures
• Focal Seizures
• Absence Seizures
• Tonic-Clonic Seizures
• End-Users:
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Homecare Settings
• Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL EPILEPSY MARKET

• 1.1 Introduction of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL EPILEPSY MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL EPILEPSY MARKET, BY TYPE

• 5.1 Overview
• 5.2 Idiopathic
• 5.3 Symptomatic
• 5.4 Cryptogenic

6 GLOBAL EPILEPSY MARKET, BY TREATMENT

• 6.1 Overview
• 6.2 Antiepileptic Drugs
• 6.3 Surgery
• 6.4 Vagus Nerve Stimulation
• 6.5 Ketogenic Diet

7 GLOBAL EPILEPSY MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Generalized Seizures
• 7.3 Focal Seizures
• 7.4 Absence Seizures
• 7.5 Tonic-Clonic Seizures

8 GLOBAL EPILEPSY MARKET, BY END-USERS

• 8.1 Overview
• 8.2 Hospitals
• 8.3 Clinics
• 8.4 Ambulatory Surgical Centers
• 8.5 Homecare Settings

9 GLOBAL EPILEPSY MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East and Africa

10 GLOBAL EPILEPSY MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Key Development Strategies

11 COMPANY PROFILES

• 11.1 UCB S.A.
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Abbott Laboratories
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 GlaxoSmithKline plc
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Bausch Health Companies Inc.
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 Sumitomo Pharma Co. Ltd
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 H. Lundbeck A/S
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Sanofi
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Viatris Inc.
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
• 11.9 Novartis AG
  • 11.9.1 Overview
  • 11.9.2 Financial Performance
  • 11.9.3 Product Outlook
  • 11.9.4 Key Developments
• 11.10 Johnson & Johnson
  • 11.10.1 Overview
  • 11.10.2 Financial Performance
  • 11.10.3 Product Outlook
  • 11.10.4 Key Developments

12 Appendix

• 12.1 Related Research